Is YKL-40 a new therapeutic target in cancer?

Bibliography

• JOHANSEN JS, JENSEN BV, ROSLIND A, NIELSEN D, PRICE PA: Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol. Biomarkers Prev. (2006) 15:194-202.
   PubMed Web of Science ®Google Scholar
• JOHANSEN JS, CINTIN C, JØRGENSEN M, KAMBY C, PRICE PA: Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur. J. Cancer (1995) 31A:1437-1442.
   PubMed Web of Science ®Google Scholar
• JENSEN BV, JOHANSEN JS, PRICE PA: High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer Res. (2003) 9:501-512.
   Web of Science ®Google Scholar
• JOHANSEN JS, CHRISTENSEN IJ, RIISBRO R et al.: High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res. Treat. (2003) 80:15-21.
   PubMed Web of Science ®Google Scholar
• CINTIN C, JOHANSEN JS, CHRISTENSEN IJ, PRICE PA, SØRENSEN S, NIELSEN HJ: Serum YKL-40 and colorectal cancer. Br. J. Cancer (1999) 79:1494-1499.
   PubMed Web of Science ®Google Scholar
• CINTIN C, JOHANSEN JS, CHRISTENSEN IJ, PRICE PA, SØRENSEN S, NIELSEN HJ: High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer (2002) 95:267-274.
   PubMed Web of Science ®Google Scholar
• DEHN H, HØGDALL EVS, JOHANSEN JS et al.: Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet. Gynaecol. Scand. (2003) 82:287-293.
   PubMed Web of Science ®Google Scholar
• HØGDALL EVS, JOHANSEN JS, KJAER SK et al.: High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol. Rep. (2003) 10:1535-1538.
   PubMed Web of Science ®Google Scholar
• DUPONT J, TANWAR MK, THALER HT et al.: Early detection and prognosis of ovarian cancer using serum YKL-40. J. Clin. Oncol. (2004) 22:3330-3339.
   PubMed Web of Science ®Google Scholar
• GRØNLUND B, HØGDALL EVS, CHRISTENSEN IJ et al.: Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA125). Int. J. Biol. Markers (2006) 21:141-148.
   PubMedGoogle Scholar
• DIEFENBACH CS, SHAH Z, IASONOS A et al.: Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol. Oncol. (2006) Epub ahead of print.
   PubMedGoogle Scholar
• JOHANSEN JS, ROSLIND A, PALLE C et al.: Serum YKL-40 levels in patients with cervical cancer are elevated compared to patients with cervical intraepithelial neoplasia and healthy controls. ASCO Ann. Meet. Proc. (2006) 24:267 (Abstract 5047).
   Google Scholar
• ROSLIND A, JOHANSEN JS, CHRISTENSEN IJ et al.: Association of serum level of YKL-40 in patients with squamous cell carcinoma of the head and neck with survival. ASCO Ann. Meet. Proc. (2006) 24:292 (Abstract 5551).
   Google Scholar
• JOHANSEN JS, DRIVSHOLM L, PRICE PA, CHRISTENSEN IJ: High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer (2004) 46:333-340.
   PubMed Web of Science ®Google Scholar
• GEERTSEN P, JOHANSEN JS, VON DER MAASE H, JENSEN BV, PRICE PA: High pretreatment serum level of YKL-40 is related to short survival in patients with advanced renal cell carcinoma treated with high-dose continuous intravenous infusion of interleukin-2. ASCO Ann. Meet. Proc. (2003) 22:399 (Abstract 1603).
   Google Scholar
• BRASSO K, CHRISTENSEN IJ, JOHANSEN JS et al.: Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate (2006) 66:503-513.
   PubMed Web of Science ®Google Scholar
• SCHMIDT H, JOHANSEN JS, GEHL J, GEERTSEN PF, FODE K, VON DER MAASE H: Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer (2006) 106:1130-1139.
   PubMed Web of Science ®Google Scholar
• SCHMIDT H, JOHANSEN JS, SJOEGREN P et al.: Serum YKL-40 predicts relapse-free and overall survival in patients with American joint committee on cancer stage I and II melanoma. J. Clin. Oncol. (2006) 24:798-804.
   PubMedGoogle Scholar
• TANWAR MK, GILBERT MR, HOLLAND EC: Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. (2002) 62:4364-4368.
   PubMed Web of Science ®Google Scholar
• HORMIGO A, GU B, KARIMI S et al.: YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res. (2006) 12:5698-5704.
   PubMed Web of Science ®Google Scholar
• BERGMANN OJ, JOHANSEN JS, KLAUSEN TW et al.: High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin. Cancer Res. (2005) 11:8644-8652.
   PubMed Web of Science ®Google Scholar
• MYLIN AK, RASMUSSEN T, JOHANSEN JS et al.: Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur. J. Haematol. (2006) 77:416-424.
   PubMed Web of Science ®Google Scholar
• JOHANSEN JS, WILLIAMSON MK, RICE JS, PRICE PA: Identification of proteins secreted by human osteoblastic cells in culture. J. Bone Miner. Res. (1992) 7:501-512.
   PubMed Web of Science ®Google Scholar
• HAKALA BE, WHITE C, RECKLIES AD: Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J. Biol. Chem. (1993) 268:25803-25810.
   PubMed Web of Science ®Google Scholar
• SHACKELTON LM, MANN DM, MILLIS AJT: Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J. Biol. Chem. (1995) 270:13076-13083.
   PubMed Web of Science ®Google Scholar
• MOHANTY AK, SINGH G, PARAMASIVAM M et al.: Crystal structure of a novel regulatory 40 kDa mammary gland protein (MGP-40) secreted during involution. J. Biol. Chem. (2003) 278:14451-14460.
   PubMed Web of Science ®Google Scholar
• DE CEUNINCK F, PASTOUREAU P, BOUET F, BONNET J, VANHOUTTE PM: Purification of guinea pig YKL-40 and modulation of its secretion by cultured articular chondrocytes. J. Cell. Biochem. (1998) 69:414-424.
   PubMed Web of Science ®Google Scholar
• MORRISON BW, LEDER P: neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene (1994) 9:3417-3426.
   PubMed Web of Science ®Google Scholar
• KIRKPATRICK RB, MATICO RE, MCNULTY DE, STRICKLER JE, ROSENBERG M: An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages. Gene (1995) 153:147-154.
   PubMed Web of Science ®Google Scholar
• KAWAMURA K, SHIBATA T, SAGET O, PEEL D, BRYANT PJ: A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells. Development (1999) 126:211-219.
   PubMed Web of Science ®Google Scholar
• REHLI M, KRAUSE SW, ANDREESEN R: Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics (1997) 43:221-225.
   PubMed Web of Science ®Google Scholar
• REHLI M, NILLER H-H, AMMON C et al.: Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J. Biol. Chem. (2003) 278:44058-44067.
   PubMed Web of Science ®Google Scholar
• HENRISSAT B, BAIROCH A: New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem. J. (1993) 293:781-788.
   PubMed Web of Science ®Google Scholar
• ARONSON NN, BLANCHARD CJ, MADURA JD: Homology modeling of glycosyl hydrolase family 18 enzymes and proteins. J. Chem. Inf. Comput. Sci. (1997) 37:999-1005.
   PubMedGoogle Scholar
• JOHANSEN JS, JENSEN HS, PRICE PA: A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br. J. Rheumatol. (1993) 32:949-955.
   PubMedGoogle Scholar
• ARIAS EB, VERHAGE HG, JAFFE RC: Complementary deoxyribonucleic acid cloning and molecular characterization of an estrogen-dependent human oviductal glycoprotein. Biol. Reproduc. (1994) 51:685-694.
   PubMed Web of Science ®Google Scholar
• BUHI WC: Characterization and biological roles of oviduct-specific, oestrogen-dependent glycoprotein. Reproduction (2002) 123:355-362.
   PubMed Web of Science ®Google Scholar
• BOOT RG, RENKEMA GH, STRIJLAND A, VAN ZONNEVELD AJ, AERTS JMFG: Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J. Biol. Chem. (1995) 270:26252-26256.
   PubMed Web of Science ®Google Scholar
• HU B, TRINH K, FIGUEIRA WF, PRICE PA: Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J. Biol. Chem. (1996) 271:19415-19420.
   PubMed Web of Science ®Google Scholar
• SAITO A, OZAKI K, FUJIWARA T, NAKAMURA Y, TANIGAMI A: Isolation and mapping of a human lung-specific gene, TSA1902, encoding a novel chitinase family member. Gene (1999) 239:325-331.
   PubMed Web of Science ®Google Scholar
• GUOPING C, FAN P, JINGXI S, XIAOPING L, SHIQIN J, YURI L: Purification and characterization of a silica-induced bronchoalveolar lavage protein with fibroblast growth-promoting activity. J. Cell Biochem. (1997) 67:257-264.
   PubMed Web of Science ®Google Scholar
• BOOT RG, BLOMMAART EFC, SWART E et al.: Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J. Biol. Chem. (2001) 276:6770-6778.
   PubMed Web of Science ®Google Scholar
• JIN HM, COPELAND NG, GILBERT DJ, JENKINS NA, KIRKPATRICK RB, ROSENBERG M: Genetic characterization of the murine Ym1 gene and identification of a cluster of highly homologous genes. Genomics (1998) 54:316-322.
   PubMed Web of Science ®Google Scholar
• OWHASHI M, ARITA H, HAYAI N: Identification of a novel eosinophil chemotactic cytokine (ECF-L) as a chitinase family protein. J. Biol. Chem. (2000) 275:1279-1286.
   PubMed Web of Science ®Google Scholar
• FUSETTI F, PIJNING T, KALK KH, BOS E, DIJKSTRA BW: Crystal structure and carbohydrate binding properties of the human cartilage glycoprotein-39. J. Biol. Chem. (2003) 278:37753-37760.
   PubMed Web of Science ®Google Scholar
• HOUSTON DR, RECKLIES AD, KRUPA JC, VAN AALTEN DMF: Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J. Biol. Chem. (2003) 278:30206-30212.
   PubMed Web of Science ®Google Scholar
• HENRISSAT B, DAVIES G: Structural and sequence-based classification of glycoside hydrolases. Curr. Opin. Struct. Biol. 1997) 7:637-644.
   PubMed Web of Science ®Google Scholar
• MILLIS AJT, HOYLE M, KENT L: In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J. Cell. Physiol. (1986) 127:366-372.
   PubMed Web of Science ®Google Scholar
• RENKEMA GH, BOOT GR, AU FL et al.: Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur. J. Biochem. (1998) 251:504-509.
   PubMedGoogle Scholar
• MALINDA KM, PONCE L, KLEINMAN HK, SHACKELTON LM, MILLIS AJT: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp. Cell Res. (1999) 250:168-173.
   PubMed Web of Science ®Google Scholar
• SJOGREN H, MEIS-KINDBLOM JM, ORNDAL C et al.: Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses. Am. J. Pathol. (2003) 162:781-792.
   PubMed Web of Science ®Google Scholar
• HUANG Y, PRASAD M, LEMON WJ et al.: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl. Acad. Sci. USA (2001) 98:15044-15049.
   PubMed Web of Science ®Google Scholar
• LAL A, LASH AE, ALTSCHUL SF et al.: A public database for gene expression in human cancers. Cancer Res. (1999) 59:5403-5407.
   PubMed Web of Science ®Google Scholar
• MARKERT JM, FULLER CM, GILLESPIE GY et al.: Differential gene expression profiling in human brain tumors. Physiol. Genomics (2001) 5:21-33.
   PubMedGoogle Scholar
• SHOSTAK K, LABUNSKYY V, DMITRENKO V et al.: HC gp-39 gene is upregulated in glioblastoma. Cancer Lett. (2003) 198:203-210.
   PubMed Web of Science ®Google Scholar
• NIGRO JM, MISRA A, ZHANG L et al.: Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. (2005) 65:1678-1686.
   PubMed Web of Science ®Google Scholar
• LAU SH, SHAM JST, XIE D et al.: Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene (2006) 25:1242-1250.
   PubMed Web of Science ®Google Scholar
• JUNKER N, JOHANSEN JS, HANSEN LT, LUND EL, KRISTJANSEN PEG: Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. (2005) 96:183-190.
   PubMed Web of Science ®Google Scholar
• PELLOSKI CE, MAHAJAN A, MAOR M et al.: YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. (2005) 11:3326-3334.
   PubMed Web of Science ®Google Scholar
• NUTT CL, BETENSKY RA, BROWER MA, BATCHELOR TT, LOUIS DN, STEMMER-RACHAMIMOV AO: YKL-40 is a differentiated diagnostic marker for histologic subtypes of high-grade gliomas. Clin. Cancer.Res. (2005) 11:2258-2264.
   PubMed Web of Science ®Google Scholar
• PELLOSKI CE, LIN E, ZHANG L et al.: Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin. Cancer Res. (2006) 12:3935-3941.
   PubMed Web of Science ®Google Scholar
• ROSLIND A, JOHANSEN JS, JUNKER N et al.: YKL-40 expression in benign and malignant lesions of the breast: a methodological study. App. Immunohistochem. Mol. Morphol. (2007) (In Press).
   Google Scholar
• JOHANSEN JS, HANSEN U, CHRISTENSEN IJ, GARBARSCH C, PRICE PA, NIELSEN HJ: YKL-40 protein expression in cancer cells and macrophages in colorectal cancer. ASCO Ann. Meet. Proc. (2005) 23:300 (Abstract 3718).
   Google Scholar
• FUKUSHIMA N, KOOPMANN J, SATO N et al.: Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod. Pathol. (2005) 18:779-787.
   PubMed Web of Science ®Google Scholar
• SCHMIDT H, ROSLIND A, JOHANSEN JS, NIELSEN DN, PRICE PA, BALSLEV E: YKL-40 expression in naevocellular naevi, carcinomas and melanomas of the skin. ASCO Ann. Meet. Proc. (2006) 24:687 (Abstract 18019).
   Google Scholar
• DVORAK HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. (1986) 315:1650-1659.
   PubMed Web of Science ®Google Scholar
• BALKWILL F, MANTOVANI A: Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-545.
   PubMed Web of Science ®Google Scholar
• COUSSENS LM, WERB Z: Inflammation and cancer. Nature (2002) 420:860-867.
   PubMed Web of Science ®Google Scholar
• BALKWILL F, COUSSENS LM: An inflammatory link. Nature (2004) 431:405-406.
   PubMed Web of Science ®Google Scholar
• DECLERCK YA, MERCURIO AM, STACK MS et al.: Proteases, extracellular matrix, and cancer. Am. J. Pathol. (2004) 164:1131-1139.
   PubMed Web of Science ®Google Scholar
• MOSS SF; BLASER MJ: Mechanisms of disease: inflammation and the origins of cancer. Review. Nat. Clin. Pract. (2005) 2:90-97.
   Google Scholar
• LEWIS JS, LEE J, UNDERWOOD JCE, HARRIS AL, LEWIS CE: Macrophage responses to hypoxia: relevance for disease mechanisms. J. Leukoc. Biol. (1999) 66:889-900.
   PubMed Web of Science ®Google Scholar
• BINGLE L, BROWN NJ, LEWIS CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. (2002) 196:254-265.
   PubMed Web of Science ®Google Scholar
• POLLARD JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. (2004) 4:71-78.
   Google Scholar
• CHEN JJW, LIN Y-C, YAO P-L et al.: Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. (2005) 23:953-964.
   PubMed Web of Science ®Google Scholar
• DIRKX AE, EGBRINK MG, WAGSTAFF J, GRIFFIOEN AW: Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. (2006) Epub ahead of print.
   PubMedGoogle Scholar
• JUNKER N, JOHANSEN JS, ANDERSEN CB, KRISTJANSEN PEG: Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer (2005) 48:223-231.
   PubMed Web of Science ®Google Scholar
• KRAUSE SW, REHLI M, KREUTZ M, SCHWARZFISHER L, PAULAUSKI JD, ANDREESEN R: Differential screening identifies genetic markers of monocyte to macrophage maturation. J. Leukoc. Biol. (1996) 60:540-545.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO S, SUZUKI T, DONG H-Y, YAMAZAKI N, MATSUSHIMA K: Serial analysis of gene expression in human monocytes and macrophages. Blood (1999) 94:837-844.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, HASHIMOTO S, TOYODA N et al.: Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood (2000) 96:2584-2591.
   PubMed Web of Science ®Google Scholar
• KIRKPATRICK RB, EMERY JG, CONNOR JR, DODDS R, LYSKO PG, ROSENBERG M: Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp. Cell Res. (1997) 237:46-54.
   PubMed Web of Science ®Google Scholar
• VERHOECKX KCM, BIJLSMA S, DE GROENE EM, WITKAMP RF, VAN DER GREED J, RODENBURG RJT: A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line. Proteomics (2004) 4:1014-1028.
   PubMed Web of Science ®Google Scholar
• BAETEN D, BOOTS AMH, STEENBAKKERS PGA et al.: Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium. Correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum. (2000) 43:1233-1243.
   PubMedGoogle Scholar
• VOLCK B, JOHANSEN JS, STOLTENBERG M et al.: Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage (2001) 9:203-214.
   PubMed Web of Science ®Google Scholar
• BOOT RG, VAN ACHTERBERG TAE, VAN AKEN BE et al.: Strong induction of members of the chitinase family of proteins in atherosclerosis. Chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler. Thromb. Vasc. Biol. (1999) 19:687-694.
   PubMed Web of Science ®Google Scholar
• JOHANSEN JS, BASLUND B, GARBARSCH C et al.: YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Artritis Rheum. (1999) 42:2624-2630.
   PubMed Web of Science ®Google Scholar
• JOHANSEN JS, MILMAN N, HANSEN M, GARBARSCH C, PRICE PA, GRAUDAL N: Increased serum YKL-40 in patients with pulmonary sarcoidosis. A potential marker of disease activity? Resp. Med. (2005) 99:396-402.
   PubMed Web of Science ®Google Scholar
• ZIEGLER-HEITBROCK HWL: Definition of human blood monocytes. J. Leukoc. Biol. (2000) 67:603-606.
   PubMed Web of Science ®Google Scholar
• BELGE K-U, DAYYANI F, HORELT A et al.: The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J. Immunol. (2002) 168:3536-3542.
   PubMed Web of Science ®Google Scholar
• DAYYANI F, BELGE K-U, FRANKENBERGER M et al.: Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes. J. Leukoc. Biol. (2003) 74:33-39.
   PubMed Web of Science ®Google Scholar
• VOLCK B, PRICE PA, JOHANSEN JS et al.: YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc. Assoc. Am. Phys. (1998) 110:351-360.
   PubMedGoogle Scholar
• SHACKEL NA, MCGUINNESS PH, ABBOTT CA, GORRELL MD, MCCAUGHAN GW: Novel differential gene expression in human cirrhosis detected by supression subtractive hybridization. Hepatology (2003) 38:577-588.
   PubMed Web of Science ®Google Scholar
• JOHANSEN JS, CHRISTOFFERSEN P, MØLLER S et al.: Serum YKL-40 is increased in patients with hepatic fibrosis. J. Hepatol. (2000) 32:911-920.
   PubMed Web of Science ®Google Scholar
• MUELLER A, O’ROURKE J, GRIMM J et al.: Distinct gene expression profiles characterize the histopathological stages of disease in helicobacter-induced mucosa-associated lymphoid tissue lymphoma. Proc. Natl. Acad. Sci. USA (2003) 100:1292-1207.
   PubMed Web of Science ®Google Scholar
• JOHANSEN JS, OLEE T, PRICE PA, HASHIMOTO S, OCHS RL, LOTZ M: Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum. (2001) 44:826-837.
   PubMed Web of Science ®Google Scholar
• STOKES DG, LIU G, COIMBRA IB, PIERA-VELAZQUEZ S, CROWL RM, JIMENEZ SA: Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis. Arthritis Rheum. (2002) 46:404-419.
   PubMed Web of Science ®Google Scholar
• IMABAYASHI H, MORI T, GOJO S et al.: Redifferentiation of dedifferentiated chondrocytes and chondrogenesis of human bone marrow stromal cells via chondrosphere formation with expression profiling by large-scale cDNA analysis. Exp. Cell Res. (2003) 288:35-50.
   PubMedGoogle Scholar
• NYIRKOS P, GOLDS EE: Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem. J. (1990) 268:265-268.
   Google Scholar
• DASURI K, ANTONOVICI M, CHEN K et al.: The synovial proteome: analysis of fibroblast-like synoviocytes. Arthritis Res. Ther. (2004) 6:R161-R168.
   PubMed Web of Science ®Google Scholar
• MILLIS AJT, HOYLE M, REICH E, MANN DM: Isolation and characterization of a Mr = 38,000 protein from differentiating smooth muscle cells. J. Biol. Chem. (1985) 260:3754-3761.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA KC, MILLIS AJT: gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp. Cell Res. (2003) 287:79-87.
   PubMed Web of Science ®Google Scholar
• DE CEUNINCK F, GAUFILLIER S, BONNAUD A, SABATINI M, LESUR C, PASTOUREAU P: YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem. Biophys. Res. Commun. (2001) 285:926-931.
   PubMed Web of Science ®Google Scholar
• RECKLIES AD, WHITE C, LING H: The chitinase 3-like protein human cartilage 39(HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase-and protein kinase B-mediated signalling pathways. Biochem. J. (2002) 365:119-126.
   PubMed Web of Science ®Google Scholar
• BENZ K, BREIT S, LUKOSCHEK M, MAU H, RICHTER W: Molecular analysis of expansion, differentiation, and growth factor treatment of human chondrocytes identifies differentiation markers and growth-related genes. Biochem. Biophys. Res. Commun. (2002) 293:284-292.
   PubMed Web of Science ®Google Scholar
• STOKES DG, LIU G, COIMBRA IB, PIERA-VELAZQUEZ S, CROWL RM, JIMENEZ SA: Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis. Arthritis Rheum. (2002) 46:404-419.
   PubMed Web of Science ®Google Scholar
• IMABAYASHI H, MORI T, GOJO S et al.: Redifferentiation of dedifferentiated chondrocytes and chondrogenesis of human bone marrow stromal cells via chondrosphere formation with expression profiling by large-scale cDNA analysis. Exp. Cell Res. (2003) 288:35-50.
   PubMedGoogle Scholar
• LING H, RECKLIES AD: The chitinase 3-like protein human cartilage glycoproein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem. J. (2004) 380:651-659.
   PubMed Web of Science ®Google Scholar
• RECKLIES AD, LING H, WHITE C, BERNIER SM: Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J. Biol. Chem. (2005) 280:41213-41221.
   PubMed Web of Science ®Google Scholar
• BIGG HF, WAIT R, ROWAN AD, CAWSTON TE: The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J. Biol. Chem. (2006) 281:21082-21095.
   PubMed Web of Science ®Google Scholar
• GREGOIRE M, LIEUBEAU B: The role of fibroblasts in tumor behavior. Cancer Met. Rev. (1995) 14:339-350.
   PubMed Web of Science ®Google Scholar
• BISSELL MJ, RADISKY D: Putting tumours in context. Nat. Rev. Cancer (2001) 1:46-54.
   PubMed Web of Science ®Google Scholar
• KENNY PA, BISSELL MJ: Tumor reversion: correction of malignant behavior by microenvironmental cues. Int. J. Cancer (2003) 107:688-695.
   PubMed Web of Science ®Google Scholar
• DRANOFF G: Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. (2004) 4:11-22.
   Google Scholar
• MIZOGUCHI E: Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. Gastroenterology (2006) 130:398-411.
   PubMed Web of Science ®Google Scholar
• MEYER MF, KREIL G: Cells expressing the DG42 gene from early Xenopus embryos synthesize hyaluronan. Proc. Natl. Acad. Sci. USA (1996) 93:4543-4547.
   PubMedGoogle Scholar
• SEMINO CE, SPECHT CA, RAIMONDI A, ROBBINS PW: Homologs of the Xenopus developmental gene DG42 are present in zebrafish and mouse and are involved in the synthesis of Nod-like chitin oligosaccharides during early embryogenesis. Proc. Natl. Acad. Sci. USA (1996) 93:4548-4553.
   PubMedGoogle Scholar
• VARKI A: Does DG42 synthesize hyaluronan or chitin? A controversy about oligosaccharides in vertebrate development. Proc. Natl. Acad. Sci. USA (1996) 93:4523-4525.
   PubMed Web of Science ®Google Scholar
• TOOLE BP: Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer (2004) 4:528-539.
   PubMed Web of Science ®Google Scholar
• FJELDSTAD K, KOLSET SO: Decreasing the metastatic potential in cancers – targeting the heparan sulfate proteoglycans. Curr. Drug Targets (2005) 6:665-682.
   PubMed Web of Science ®Google Scholar
• ATKINSON AJ Jr: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. (2001) 69:89-95.
   PubMed Web of Science ®Google Scholar
• WERNER M, FRASER C, SILVERBERG M: Clinical utility and validation of emerging biochemical markers for mammary adenocarcinoma. Clin. Chem. 1993) 39:2386-2396.
   PubMedGoogle Scholar
• HARVEY S, WEISMAN M, O’DELL J et al.: Chondrex: new marker of joint disease. Clin. Chem. (1998) 44:509-516.
   PubMed Web of Science ®Google Scholar
• MAHANEY MC, CZERWINSKI SA, ROGERS J: Genetic effects on serum levels of human cartilage glycoprotein-39 (YKL-40) in a pedigreed baboon model for age-related changes and pathology in bone. Am. Soc. Bone Miner. Res. (1998): Abstract SA121.
   Google Scholar
• REGISTER TC, CARLSON CS, ADAMS MR: Serum YKL-40 is associated with osteoarthritis and atherosclerosis in nonhuman primates. Clin. Chem. (2001) 47:2159-2161.
   PubMed Web of Science ®Google Scholar
• JOHANSEN JS, HVOLRIS J, HANSEN M, BACKER V, LORENZEN I, PRICE PA: Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br. J. Rheumatol. (1996) 35:553-559.
   PubMedGoogle Scholar
• JOHANSEN JS, STOLTENBERG M, HANSEN M et al.: Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (1999) 38:618-626.
   PubMed Web of Science ®Google Scholar
• VOS K, STEENSBAKKERS P, MILTENBURG AMM et al.: Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. (2000) 59:544-548.
   PubMed Web of Science ®Google Scholar
• JOHANSEN JS, KIRWAN JR, PRICE PA, SHARIF M: Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand. J. Rheumatol. (2001) 30:297-304.
   PubMed Web of Science ®Google Scholar
• KOUTROUBAKIS IE, PETINAKI E, DIMOULIOS P et al.: Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int. J. Colorectal Dis. (2003) 18:287-293.
   Google Scholar
• VIND I, JOHANSEN JS, PRICE PA, MUNKHOLM P: Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand. J. Gastroenterol. (2003) 38:599-605.
   PubMed Web of Science ®Google Scholar
• NORDENBAEK C, JOHANSEN JS, JUNKER P, BORREGAARD N, SØRENSEN O, PRICE PA: YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J. Infect. Dis. (1999) 180:1722-1726.
   PubMed Web of Science ®Google Scholar
• KRONBORG G, ØSTERGAARD C, WEIS N et al.: Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated to the outcome of the disease. Scand. J. Infect. Dis. (2002) 34:323-326.
   PubMed Web of Science ®Google Scholar
• ØSTERGAARD C, JOHANSEN JS, BENFIELD T, PRICE PA, LUNDGREN JD: YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin. Diagn. Lab. Immunol. (2002) 9:598-604.
   PubMedGoogle Scholar
• JOHANSEN JS, KRABBE K, MØLLER K, PEDERSEN BK: Circulating YKL-40 levels during human endotoxaemia. Clin. Exp. Immunol. (2005) 140:343-348.
   PubMed Web of Science ®Google Scholar
• KAYNAR MY, TANRIVERDI T, KAFADAR AM et al.: YKL-40 levels in the cerebrospinal fluid and serum of patients with aneurysmal subarachoid hemorrhage: preliminary results. J. Clin. Neuroscience (2005) 12:754-757.
   Google Scholar
• JOHANSEN JS, MØLLER S, PRICE PA et al.: Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand. J. Gastroenterol. (1997) 32:582-590.
   PubMed Web of Science ®Google Scholar
• TRAN A, BENZAKEN S, SAINT-PAUL M-C et al.: Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur. J. Gastroenterol. Hepatol. (2000) 12:989-993.
   PubMed Web of Science ®Google Scholar
• NØJGAARD C, JOHANSEN JS, CHRISTENSEN E et al.: Serum YKL-40 and PIIINP levels as prognostic markers in patients with alcoholic liver disease. J. Hepatol. (2003) 39:179-186.
   PubMed Web of Science ®Google Scholar
• NØJGAARD C, JOHANSEN JS, KRARUP HB et al.: Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C. Scand. J. Gastroenterol. (2003) 38:659-665.
   PubMed Web of Science ®Google Scholar
• KELLEHER TB, MEHTA SH, BHASKAR R et al.: Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J. Hepatol. (2005) 43:78-84.
   PubMed Web of Science ®Google Scholar
• NUNES D, FLEMMING C, OFFNER G et al.: HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J. Acquir. Immune. Defic. Syndr. (2005) 40:538-544.
   PubMed Web of Science ®Google Scholar
• ZHENG M, CAI WM, ZHAO JK, ZHU SM, LIU RH: Determination of serum levels of YKL-40 and hyaluronic acid in patients with hepatic fibrosis due to schistosomiasis japonica and appraisal of their clinical value. Acta. Trop. (2005) 96:148-152.
   PubMed Web of Science ®Google Scholar
• KAMAL SM, TURNER B, HE Q et al.: Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology (2006) 43:771-779.
   PubMed Web of Science ®Google Scholar
• GABAY C, KUSHNER I: Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. (1999) 340:448-454.
   PubMed Web of Science ®Google Scholar
• KUSHNER I, RZEWNICKI D, SAMOLS D: What does minor elevation of C-reactive protein signify? Am. J. Med. (2006) 119:17-28.
   PubMedGoogle Scholar